Joyce Ching Mei Lam

Dr. Joyce Ching Mei Lam

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2004 in Pediatric Surgery International
Verified
Journal Article
Closed access
PDF file
JLJoyce Ching Mei Lam
Joyce Ching Mei Lam
CCC. H. Chui
C. H. Chui
AJA. S. Jacobsen
A. S. Jacobsen
ATA. M. Tan
A. M. Tan
VJV. T. Joseph
V. T. Joseph

10 September 2018 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AYAllen Eng Juh Yeoh
Allen Eng Juh Yeoh
YLYi Lu
Yi Lu
WCWinnie Hui Ni Chin
Winnie Hui Ni Chin
ECEdwynn Kean Hui Chiew
Edwynn Kean Hui Chiew
ELEvelyn Huizi Lim
Evelyn Huizi Lim
HAHany Ariffin
Hany Ariffin
Purpose: Although IKZF1 deletion ( IKZF1del) confers a higher risk of relapse in childhood B-cell acute lymphoblastic leukemia (B-ALL), it is uncertain whether treatment intensification will reverse this risk and improve outcomes. The Malaysia-Singapore ALL 2010 study (MS2010) prospectively upgraded the risk assignment of patients with IKZF1del to the next highest level and added imatinib to the treatment of all patients with BCR- ABL1 fusion. Patients and Methods: In total, 823 patients with B-ALL treated in the Malyasia-Singapore ALL 2003 study (MS2003; n = 507) and MS2010 (n = 316) were screened for IKZF1del using the multiplex ligation-dependent probe amplification assay. The impact of IKZF1del on the 5-year cumulative incidence of relapse (CIR) was compared between the two studies. Results: Patient characteristics were similar in both cohorts, including IKZF1del frequencies (59 of 410 [14.4%] v 50 of 275 [18.2%]; P = .2). In MS2003, where IKZF1del was not used in risk assignment, IKZF1del conferred a significantly higher 5-year CIR (30.4% v 8.1%; P = 8.7 × 10−7), particularly in the intermediate-risk group who lacked high-risk features (25.0% v 7.5%; P = .01). For patients with BCR-ABL1–negative disease, IKZF1del conferred a higher 5-year CIR (20.5% v 8.0%; P = .01). In MS2010, the 5-year CIR of patients with IKZF1del significantly decreased to 13.5% ( P = .05) and no longer showed a significant difference in patients with BCR-ABL1-negative disease (11.4% v 4.4%; P = .09). The 5-year overall survival for patients with IKZF1del improved from 69.6% in MS2003 to 91.6% in MS2010 ( P = .007). Conclusion: Intensifying therapy for childhood B-ALL with IKZF1del significantly reduced the risk of relapse and improved overall survival. Incorporating IKZF1del screening significantly improved treatment outcomes in contemporary ALL therapy.

30 September 2020 in Blood Advances
Verified
Journal Article
Open access
PDF file
KTKatharina Thom
Katharina Thom
ALAnthonie W. A. Lensing
Anthonie W. A. Lensing
INIldar Nurmeev
Ildar Nurmeev
FBFanny Bajolle
Fanny Bajolle
Damien BonnetDamien Bonnet
Damien Bonnet
CMChristoph Male
Christoph Male
Anticoagulant treatment of pediatric central venous catheter–related venous thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 children with any VTE received rivaroxaban or standard anticoagulants. A predefined analysis of the CVC-VTE cohort was performed. Children with CVC-VTE (age, birth to 17 years) were administered rivaroxaban or standard anticoagulants during the 1-month (children <2 years) or 3-month (all other children) study period. Predefined outcomes were recurrent VTE, change in thrombotic burden on repeat imaging, and bleeding. Predictors for continuation of anticoagulant therapy beyond the study period were evaluated. One hundred twenty-six children with symptomatic (n = 76, 60%) or asymptomatic (n = 50, 40%) CVC-VTE received either rivaroxaban (n = 90) or standard anticoagulants (n = 36). There was no recurrent VTE (0%; 95% confidence interval [CI], 0.0%-2.8%). Three children had the principal safety outcome: none had major bleeding and 3 children had clinically relevant nonmajor bleeding (2.4%; 95% CI, 0.7%-6.5%), all in the rivaroxaban arm. Complete or partial vein recanalization occurred in 57 (55%) and 38 (37%) of 103 evaluable children, respectively. Results were similar for symptomatic and asymptomatic CVC-VTE. Continuation of anticoagulant therapy beyond the study period occurred in 61 (48%) of children and was associated with residual VTE but only in children <2 years (odds ratio [OR], 20.9; P = .003) and continued CVC use (OR, 6.7; P = .002). Anticoagulant therapy appeared safe and efficacious and was associated with reduced clot burden in most children with symptomatic or asymptomatic CVC-VTE. Residual VTE and continued CVC use were associated with extended anticoagulation. This trial was registered at www.clinicaltrials.gov as #NCT02234843.

1 September 2019 in International Journal of Gynecological Pathology
Verified
Journal Article
Closed access
NKNicholas Wee Chong Koh
Nicholas Wee Chong Koh
WSWan Yi Seow
Wan Yi Seow
YLYork Tien Lee
York Tien Lee
JLJoyce Ching Mei Lam
Joyce Ching Mei Lam
DLDerrick Wen Quan Lian
Derrick Wen Quan Lian
We report the first case of an ovarian pericytoma with t(7;12). An 11-year-old child presented with abdominal pain and distension. A suprapubic mass was detected on examination and radiological investigations revealed a 16.5 cm solid-cystic ovarian mass. Histologically, the tumor was composed of spindle cells with S100-protein, Bcl-2, and CD10 reactivity on immunohistochemistry. Alpha fetoprotein, calretinin, alpha-inhibin, WT1, smooth muscle actin, caldesmon, desmin, cytokeratins, chromogranin, synaptophysin, EMA, Sox10, CD117, CD31, CD34, and CD68 were all negative. Molecular tests showed t(7;12)(p22;q13), resulting in the fusion of the ACTB with GLI1 genes and a diagnosis of pericytoma with t(7;12) of the ovary was made. We discuss the difficulties in diagnosing this lesion in the ovary and highlight the importance on molecular tests in characterizing challenging cases, especially primary ovarian spindle cell mesenchymal tumors.

1 August 2019 in Journal of Medical Microbiology
Verified
Journal Article
Open access
JCJ. C. Chan
J. C. Chan
CCChiayin Chong
Chiayin Chong
KTKoh Cheng Thoon
Koh Cheng Thoon
NTN. W. S. Tee
N. W. S. Tee
MMMatthias Maiwald
Matthias Maiwald
NTNatalie Woon Hui Tan
Natalie Woon Hui Tan
Objectives. Elizabethkingia meningoseptica is a multi-drug-resistant organism that is associated with high mortality and morbidity in newborn and immunocompromised patients. This study aimed to identify the best antimicrobial therapy for treating this infection. Methods. A retrospective descriptive study was conducted from 2010 to 2017 in a tertiary paediatric hospital in Singapore. Paediatric patients aged 0 to 18 years old with a positive culture for E. meningoseptica from any sterile site were identified from the hospital laboratory database. The data collected included clinical characteristics, antimicrobial susceptibility and treatment, and clinical outcomes. Results. Thirteen cases were identified in this study. Combination therapy with piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluoroquinolone resulted in a cure rate of 81.8 %. The mortality rate was 15.4 % and neurological morbidity in patients with bacteraemia and meningitis remained high (75 %). Conclusions. Treatment with combination therapy of piperacillin/tazobactam and trimethoprim/sulfamethoxazole or a fluroquinolone was effective in this study, with low mortality rates being observed.

1 May 2015 in Pediatric Neurology
Verified
Journal Article
Closed access
CCCristelle Chow
Cristelle Chow
MFMarielle Valerie Fortier
Marielle Valerie Fortier
LDLena Das
Lena Das
AMAnuradha P. Menon
Anuradha P. Menon
RVRashida Vasanwala
Rashida Vasanwala
TTThomas Terrence
Thomas Terrence